Effects of Bariatric Surgery and Lifestyle Changes on Fat and Liver Health
Change of Adipose Tissues and Triglyceride in Obese Patients With Non-alcoholic Fatty Liver Disease After Bariatric Surgery or Life-style Intervention
This study is testing how bariatric surgery and lifestyle changes affect fat and liver health in people with obesity and related metabolic issues.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong, Shatin) |
| Trial ID | NCT03875625 on ClinicalTrials.gov |
What this trial studies
This study aims to quantify changes in adipose tissues, liver triglycerides, and cholesterol levels following lifestyle interventions or bariatric surgery in patients with obesity and related metabolic disorders. It will investigate the role of brown adipose tissue as a potential biomarker for non-alcoholic fatty liver disease (NAFLD) and explore the relationship between brown fat, obesity, and NAFLD. The research will involve measuring various adipose tissue types and assessing liver inflammation and fibrosis through biopsies.
Who should consider this trial
Good fit: Ideal candidates include individuals with a BMI of 25 or higher, particularly those with metabolic syndrome or morbid obesity.
Not a fit: Patients with other hepatic diseases or those on medications affecting liver fat may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into effective treatments for obesity and NAFLD, potentially improving patient outcomes and quality of life.
How similar studies have performed: Previous studies have shown associations between obesity and NAFLD, but the specific role of brown adipose tissue as a biomarker is still being explored, making this approach novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * BMI ≥ 25-30 kg/m2 * BMI ≥ 30 kg/m2 with Metabolic syndrome * BMI ≥ 35 kg/m2 for morbid obesity Exclusion Criteria: * Other kind of hepatic diseases * Under medications known to affect liver fat * Waist circumference ≥ 150 cm * Weight ≥ 250 kg * MRI contraindications
Where this trial is running
Hong Kong, Shatin
- The Chinese University of Hong Kong, Prince of Wale Hospital — Hong Kong, Shatin, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Winnie C Chu, MD — Chinese University of Hong Kong
- Study coordinator: Winnie C Chu, MD
- Email: winniechu@cuhk.edu.hk
- Phone: (852) 3505 2299
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.